Study the Mechanism and Effectiveness of Probiotics on Atopic Dermatitis
Key facts
- Who runs it
- National Cheng-Kung University Hospital
- Where
- Taiwan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Enrolling by invitation
- People taking part
- 90 people, planned
- Started
- 30 Jun 2026
- Expected to end
- 31 Dec 2030
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Probiotic 2 × 10^8
- Placebo capsule
- Probiotic 2 × 10^10
- Record updated
- 16 November 2026
Who can take part
- Age
- 3 years to 18 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Aged 3 to 18 years
- Diagnosis of atopic dermatitis with moderate-to-severe disease, defined as an Eczema Area and Severity Index (EASI) score > 7 at screening
- Receiving regular atopic dermatitis treatment at National Cheng Kung University Hospital
- Written informed consent from the participant's legal representative, with assent from participants aged 7 years and older
Who cannot take part
- Current or planned treatment with a biologic agent (e.g., dupilumab, an anti-IL-4Rα antibody)
- Current or planned treatment with an oral small-molecule immunosuppressant (e.g., upadacitinib)
- Skin disease other than atopic dermatitis
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 3 and 18 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn whether probiotics isolated from breast milk and healthy infant feces can reduce the severity of atopic dermatitis (eczema) in children aged 3 to 18 years with moderate-to-severe disease. The main questions it aims to answer are:
Read full original descriptionShow less
* Does taking the probiotic capsule twice daily for 12 weeks reduce eczema severity, measured by the EASI SCORAD? * Does the probiotic improve quality of life, blood markers of allergic inflammation (IgE, histamine, IL-31, T-cell subsets), and gut microbiota composition? Researchers will compare the probiotic to a placebo capsule that looks the same but contains no probiotic bacteria.
Participants will:
* Take one capsule twice daily for 12 weeks, in addition to their usual atopic dermatitis treatment * Complete the PO-SCORAD and a quality-of-life questionnaire at baseline and weeks 2, 4, 8 and 12 * Provide stool samples at baseline and weeks 4 and 12, and a 10 mL blood sample at baseline and week 12.
The 3 groups in the trial
- Probiotic 2*10^8Treatment being tested
One probiotic(2\*10\^8) twice daily for 12 weeks, in addition to regular atopic dermatitis treatment.
- Probiotic 2*10^10Treatment being tested
One probiotic(2\*10\^10) twice daily for 12 weeks, in addition to regular atopic dermatitis treatment.
- PlaceboPlacebo, for comparison
One identical-appearing placebo capsule twice daily for 12 weeks, in addition to regular atopic dermatitis treatment.
Treatment: Placebo capsule
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Revolutionary Concept of X-biotics for Correcting Disease-associated Microbiota Compositions: Focus on Atopic, Gastrointestinal, Neurological, and Metabolic Disease: Study the Mechanism and Effectiveness of Probiotics on Atopic Dermatitis
- Criteria questions
- Built from NCT07937592, who can take part
- Record updated
- 16 November 2026